Drug reference

prothionamide

Antitubercular drug · Antitubercular

Antitubercular drugAntitubercular

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

Prothionamide is a close congener of ethionamide, resembling it in antimycobacterial property and mechanism of action (interfering with mycolic acid synthesis).

Indications

MDR-TB (interchangeable with ethionamide)MAC infection (interchangeable with ethionamide)

Pharmacokinetics

Onset

Not mentioned in text, omitted as per instructions to not interpolate.

Related guidelines

Skin and soft tissue infections

IDSA · Infectious Diseases · 2010

Hepatitis B — chronic infection

EASL · Gastroenterology · 2025

Urinary tract infection

EAU · Urology · 2024

Latent tuberculosis infection

RNTCP · Infectious Disease · 2023

Helicobacter pylori infection

ICMR · Gastroenterology · 2021

Ask House about prothionamide

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team